GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Curaleaf Holdings Inc (OTCPK:CURLF) » Definitions » Debt-to-EBITDA

Curaleaf Holdings (Curaleaf Holdings) Debt-to-EBITDA : 3.05 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Curaleaf Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Curaleaf Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $131 Mil. Curaleaf Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $741 Mil. Curaleaf Holdings's annualized EBITDA for the quarter that ended in Mar. 2024 was $286 Mil. Curaleaf Holdings's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 3.05.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Curaleaf Holdings's Debt-to-EBITDA or its related term are showing as below:

CURLF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.09   Med: 4.7   Max: 12.25
Current: 4.67

During the past 10 years, the highest Debt-to-EBITDA Ratio of Curaleaf Holdings was 12.25. The lowest was -2.09. And the median was 4.70.

CURLF's Debt-to-EBITDA is ranked worse than
78.21% of 661 companies
in the Drug Manufacturers industry
Industry Median: 1.7 vs CURLF: 4.67

Curaleaf Holdings Debt-to-EBITDA Historical Data

The historical data trend for Curaleaf Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curaleaf Holdings Debt-to-EBITDA Chart

Curaleaf Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.25 3.22 2.70 5.53 4.70

Curaleaf Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.36 3.96 5.87 9.45 3.05

Competitive Comparison of Curaleaf Holdings's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Curaleaf Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Curaleaf Holdings's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Curaleaf Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Curaleaf Holdings's Debt-to-EBITDA falls into.



Curaleaf Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Curaleaf Holdings's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(64.899 + 818.648) / 187.93
=4.70

Curaleaf Holdings's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(130.688 + 740.978) / 286.224
=3.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Curaleaf Holdings  (OTCPK:CURLF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Curaleaf Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Curaleaf Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Curaleaf Holdings (Curaleaf Holdings) Business Description

Traded in Other Exchanges
Address
420 Lexington Avenue, Suite 2035, New York, NY, USA, 10170-0052
Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the U.S. The company has operations in 18 states. Its brands include Curaleaf, UKU, Select, and Grassroots. The company acquired EMMAC Life Sciences in March 2021, beginning its foray into the global medical market in competition with Canadian cannabis producers.